Medtech Talk

Miromatrix CEO Jeff Ross Shares the Bold Plan to Eliminate the Organ Transplant Waiting List

01.11.2019 - By HealthegyPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Miromatrix straddles the line between biotech and medtech. The start-up is developing a line of “ghost organs” that can be used in humans. The technology is moving fast, and Ross hopes to have clinical trials up and running by the end of 2020. The future is here. Also, I’ll announce a keynote speaker for the May 30 Medtech Conference. 

More episodes from Medtech Talk